- Report
- June 2026
- 800 Pages
Global
From €2677EUR$3,000USD£2,301GBP
- Report
- February 2026
- 250 Pages
Global
From €4007EUR$4,490USD£3,444GBP
- Report
- January 2026
- 180 Pages
Global
From €4016EUR$4,500USD£3,451GBP
- Report
- November 2025
- 200 Pages
Global
From €7095EUR$7,950USD£6,098GBP
- Report
- November 2025
- 200 Pages
Global
From €7095EUR$7,950USD£6,098GBP
- Report
- November 2024
- 600 Pages
Global
From €2945EUR$3,300USD£2,531GBP
- Report
- July 2025
Global
From €4373EUR$4,900USD£3,758GBP
- Report
- March 2023
- 117 Pages
Global
From €4016EUR$4,500USD£3,451GBP
- Report
- July 2026
- 224 Pages
Global
From €7131EUR$7,990USD£6,128GBP
- Drug Pipelines
- September 2024
- 247 Pages
Global
From €7095EUR$7,950USD£6,098GBP
- Report
- June 2025
- 400 Pages
Global
From €4417EUR$4,949USD£3,796GBP
Somatuline is a brand of oncology drugs used to treat a variety of cancers, including neuroendocrine tumors, prostate cancer, and breast cancer. It is a long-acting somatostatin analogue, meaning it works by blocking the release of hormones that can cause cancer cells to grow. It is administered via subcutaneous injection, and is typically used in combination with other treatments such as chemotherapy and radiation therapy.
Somatuline is manufactured by Ipsen, a French pharmaceutical company, and is available in the United States, Canada, and Europe. It is also available in other countries through Ipsen's international distribution network. Other companies that produce similar drugs include Novartis, Merck, and Pfizer. Show Less Read more